Drug Trial Radar · NCT05891093
Efficacy and Safety of Fluzoparib Combined With Adjuvant Endocrine Therapy for HR+/HER2- SNF3-subtype Early Breast Cancer (BCTOP-L-A01)
Last checked: Nov 19, 2026Latest source record: Feb 8, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
766
Planned (sponsor's estimate)
Start
Jun 1, 2023
Primary completion
May 31, 2028
Study completion May 31, 2031
Sponsor
- Lead sponsor
- Fudan UniversityAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Jun 6, 2023
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Female only, from 18 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a prospective, randomized, open-label phase III clinical study on the efficacy and safety of fluzoparib combined with adjuvant endocrine therapy versus adjuvant endocrine therapy for HR+/HER2- SNF3-subtype early breast cancer.
Conditions
- Breast Cancer
Interventions
FluzoparibDrug
Fluzoparib 50mg bid orally for 1 year.
AnastrozoleDrug
1mg, qd orally
LetrozoleDrug
2.5mg, qd orally
ExemestaneDrug
25mg, qd orally
TamoxifenDrug
10mg, bid orally
ToremifeneDrug
60mg, qd orally
AbemaciclibDrug
150mg/100mg/50mg, bid orally for 2 years
LHRH agonistDrug
Leuprorelin acetate, goserelin acetate
Primary outcomes
What the sponsor says the trial is designed to measure.
- invasive disease free survival (iDFS)Time frame: 5 years
Locations
15 sites in 1 country. Site status is shown where the registry gives one.
Beijing Cancer Hospital
Beijing, Beijing Municipality, China · Recruiting
Chongqing Cancer Hospital
Chongqing, Chongqing Municipality, China · Recruiting
Fujian Medical University Union Hospital
Fuzhou, Fujian, China · Recruiting
Guangdong Academy of Medical Sciences Guangdong Provincial People's Hospital
Guangzhou, Guangdong, China · Recruiting
Sun Yat-sen University Cancer Center
Guangdong, Guangzhou, China · Recruiting
Affiliated Hospital of Nantong University
Nantong, Jiangsu, China · Recruiting
Northern Jiangsu People's Hospital
Yangzhou, Jiangsu, China · Recruiting
The First Hospital of China Medical University
Shenyang, Liaoning, China · Recruiting
Liaoning Cancer Hospital & Institute
Shenyang, Liaoning, China · Recruiting
Fudan University Shanghai Cancer Center
Shanghai, Shanghai Municipality, China · Recruiting
Shanghai Sixth People's Hospital Affiliated to Shanghai Jiaotong University
Shanghai, Shanghai Municipality, China · Recruiting
Shanghai First Maternity and Infant Hospital
Shanghai, Shanghai Municipality, China · Recruiting
The First Affiliated Hospital of Xi'an Jiaotong University
Xi’an, Shanxi, China · Recruiting
West China Hospital of Sichuan University
Chengdu, Sichuan, China · Recruiting
Ningbo Medical Center Lihuili Hospital
Ningbo, Zhejiang, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.